COVID-19 Vaccines

FDA & CDC call for a pause in Johnson & Johnson vaccine

The FDA and the CDC will stop using the COVID-19 vaccine at federal sites urging states to follow suit while they examine the safety issues.

The FDA and the CDC have announced that they were “reviewing data involving six cases of a rare and severe type of blood clot in individuals after receiving the Johnson & Johnson vaccine”.

The announcement stated that the clotting in question was called cerebral venous sinus thrombosis (CVST) which required a different treatment than the usual anticoagulant drug called heparin that “may be dangerous”, it said.

Pending further investigation, the FDA and CDC called for “a pause in the use of this vaccine out of an abundance of caution” to “ensure that the health care provider community is aware of the potential for these adverse events”.

All six blood clot cases were in women aged between 18 and 48, with symptoms six to 13 days after vaccination.

According to The New York Times officials have confirmed one woman had died and a second, in Nebraska, was in a critical condition.

The joint statement further stated, “people who have received the J&J vaccine who develop severe headache, abdominal pain, leg pain, or shortness of breath within three weeks after vaccination should contact their health care provider”.

It is likely that the federal government will now halt the use of the vaccine in all federally-run vaccination sites and expect state-run sites to do the same.

The US health protection agency has also identified a very small number of the same rare form of blood clots seen in people given the AstraZeneca jab.